



## Curriculum Vitae

Personal information **Hugues Malonne**

### Work experience

---

1. Employer: Federal Agency for Medicines and Health Products
  - Start date: 092023
  - End date:
  - Position: Chief Executive Officer a.i.
  - Activities: • The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products.
  - Country: Belgium
2. Employer: Federal Agency for Medicines and Health Products
  - Start date: 042022
  - End date:
  - Position: Director General Pre authorisation
  - Activities: • The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Pre Authorization is in charge of all the activities taking place before the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions and 2 units: the R&D Division, the Marketing Authorization Division, the Veterinary Medicine Division, the Evaluator Division, the National Innovation Office and the Pharmacopeia/API unit. The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Pre Authorization is in charge of all the activities taking place before the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions and 2 units: the R&D Division, the Marketing Authorization Division, the Veterinary Medicine Division, the Evaluator Division, the National Innovation Office and the Pharmacopeia/API unit.
  - Country: Belgium
3. Employer: Federal Agency for Medicines and Health Products
  - Start date: 022017
  - End date: 032022
  - Position: Director General Post authorisation
  - Activities: The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Post Authorization is in charge of all the activities taking place after the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions: the Post Authorization Division, the Vigilance Division, the Healthcare Products Division and the Proper Use Division.
  - Country: Belgium
4. Employer: University of Namur
  - Start date: 092018
  - End date:
  - Position: Invited Professor
  - Activities: Part\_time activity in the fields of pharmacology, healthcare innovation and financing.
  - Country: Belgium
5. Employer: Université libre de Bruxelles
  - Start date: 062013
  - End date:
  - Position: Professor
  - Activities: Part\_time activity in the fields of pharmacology, healthcare innovation and financing.
  - Country: Belgium
6. Employer: Luxembourg Institute of Health/Integrated Biobank of Luxembourg
  - Start date: 062013
  - End date: 122019
  - Position: Independent Director, Board of Directors
  - Activities: The Luxembourg Institute of Health is the result of the merger of former Centre de Recherche Public\_ Santé and the Integrated Biobank of Luxembourg. The Luxembourg Institute of Health is a public biomedical research organization. Striving for excellence, its researchers, by their creativity, enthusiasm and commitment, generate knowledge on disease mechanisms and contribute to the development of new diagnostics, innovative therapies and clinical applications that impact the healthcare of Luxembourgish and European citizens. The activities of the Luxembourg Institute of Health are developed within the following research topics: Oncology, Infection and Immunity, Population Health. The IBBL (Integrated BioBank of Luxembourg) Institute is a biobank dedicated to supporting biomedical research for the benefit of patients. The mission of IBBL is to provide high quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare solutions. IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. The Board of Directors oversees all the above mentioned activities.
  - Country: Luxembourg
7. Employer: Alpine Partners AG
  - Start date: 062013
  - End date: 012017
  - Position: Managing Partner
  - Activities: Based in Lucerne, Alpine Partners is a boutique consulting firm specializing in

.

healthcare innovation. We provide a large set of services and expertise in the fields of Market Access (pricing and reimbursement), Public-Private Partnerships, Medical/Scientific Affairs, Training/coaching and Marketing Strategy. Our clients are global healthcare companies (pharmaceuticals, medical devices, diagnostics and consumer goods), mid-sized biotech firms, governmental bodies and NGOs.

- Country: Switzerland
- 8. Employer: Abbott Laboratories
  - Start date: 122011
  - End date: 122012
  - Position: Divisional Director, Global Value Proposition, EPD HQ
  - Activities: Market Access Leadership Team member, reporting to the Global Head of Market Access Member of the EMEA West Leadership Team, dotted\_line reporting to the Area Vice\_President EMEA\_W\* Core job responsibilities: \_ Define EPD Global Value Proposition versus pure generics, analyze potential value dimensions and hypothesis \_ Collaborate with external opinion leaders and research groups to generate public health evidences to sustain value claims \_ Design and execute Outcomes Research projects and initiatives to support the Value Proposition \_ Provide guidance on related health policy platform engagement in close collaboration with government affairs colleagues, country GMs and Area VPs \_ Monitor health policy environment, anticipate trend and changes, proactively adjust and adapt EPD Value Proposition and related activities \_ Provide strategic input into portfolio optimization to support/enhance EPD Value Proposition \* Support the country separation process for EMEA\_W providing guidance for the newly created country and area level Market Access & Policy structure
  - Country: Switzerland
- 9. Employer: MSD (Merck & Co)
  - Start date: 012009
  - End date: 122011
  - Position: Head, Public Policy & HEOR (later Public Policy & Market Access)
  - Activities: Country Management Team member, reporting to the Chairman and President MSD China Health Outcomes: Managed and coached a team of 7 people who develop and implement outcomes research studies and initiatives supporting key therapeutic areas (ID, Diabetes, Ophthalmology, CV, Respiratory, Vaccines, Oncology) Major achievements: \_ Developed and implemented one of the largest real world outcomes study for patients with type 2 diabetes (acronym: 3B, 25000 patients) and its extension Public Policy: Led a team of 3 people to develop, launch and implement innovative multi\_year Public-Private Partnerships in ID and CV\_metabolism Major achievements: \_Partnership with the Sichuan Health Bureau on integrated and standardized management of hypertension, dyslipidemia, and type 2 diabetes (target population for pilot phase: 2 million inhabitants) \_Partnership with China Center for Disease Control and Prevention on viral hepatitis (includes health outcomes research, medical and public education, health policy advocacy) \_Several partnerships with City Governments on chronic disease management
  - Country: China
- 10. Employer: MSD (Merck & Co)
  - Start date: 2005
  - End date: 2009
  - Position: External Affairs Director, MSD Belgium\_Luxembourg
  - Activities: In charge of Market Access, Governmental Affairs and Public Relations (Spokesperson) Country Management Team member, reporting to the General Manager MSD Belgium Head of a team of 12 people
  - Country: Belgium
- 11. Employer: Université libre de Bruxelles
  - Start date: 1999
  - End date: 2005
  - Position: Senior Lecturer\_Associate Professor\_Professor
  - Activities: Extensive teaching and research experience in: Pharmacology (pharmacokinetics and pharmacodynamics) Pharmaceutics and Biopharmaceutics Ethics and Regulations (including Market Access)
  - Country: Belgium

## Education and training

---

1. Subject: Solvay Brussels School (Université libre de Bruxelles)
  - Start date: 102015
  - End date: 102016
  - Qualification: Executive Master in Healthcare Management (MMISS)
  - Organisation: Hospital and Health Care Facilities Administration/Management
  - Country: Belgium
2. Subject: Harvard Medical School
  - Start date: 032011
  - End date: 032011
  - Qualification: Certificate in Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis
  - Organisation: Oncology continuing education program
  - Country: United States
3. Subject: Université libre de Bruxelles
  - Start date: 1993
  - End date: 1999
  - Qualification: PhD, Pharmaceutical Sciences (Pharmacology)
  - Organisation: Pre\_clinical pharmacology Oncology Biopharmaceutics and pharmaceutics
  - Country: Belgium
4. Subject: Université libre de Bruxelles
  - Start date: 1988
  - End date: 1993
  - Qualification: Pharmacist (PharmD)
  - Organisation:
  - Country: Belgium

## Additional information

---

### Publications

1. Study of potential depot systems composed of polar lipids and water including various hydrophilic and hydrophobic drugs H. MALONNE, A.J. MOËS, J. FONTAINE. Acta Technologiae et Legis Medicamenti, 1996, 1(3), 165\_170. 2. Le traitement de la douleur dans le cadre de l'officine H. MALONNE, L. LEEMANS, J. FONTAINE. J. Pharm. Belg., 1996, 2.1(6), 305\_315. 3. Pijn in de officina: farmacologische beschouwingen deel I L. LEEMANS, H. MALONNE, G. LAEKEMAN. Farm. Tijdschr., 1996, 2(12), 3\_12. 4. Pijn in de officina: communicatie als hoofdoel van het baliegebeuren deel II L. LEEMANS, H. MALONNE, G. LAEKEMAN. Farm. Tijdschr., 1996, 2(12), 13\_17. 5. DNA topoisomerases targeting drugs: mechanisms of action and perspectives H. MALONNE, G. ATASSI. Anticancer Drugs, 1997, 11(9), 811\_822. 6. Les interactions médicamenteuses: I Principes généraux H. MALONNE, J. FONTAINE. J.

Pharm. Belg., 1997, 52(1), 41\_48. 7. Les interactions médicamenteuses: II Exemples rencontrés dans le traitement des pathologies digestives H. MALONNE, J. FONTAINE. J. Pharm. Belg., 1997, 52(2), 65\_68. 8. Topical anti-inflammatory activity of new 2-(1-indolizyl)propionic acid derivatives in mice H. MALONNE, J. HANUISE, J. FONTAINE. Pharm. Pharmacol. Commun., 1998, 1(3), 241\_244. 9. Interactions entre médicaments et aliments modifiant l'absorption du principe actif H. MALONNE. Dieta, 1998, 11, 14\_18. 10. Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma S. FARINELLE, R. DEDECKER, H. MALONNE, J. WERRY, F. DARRO, R. KISS. Anticancer Res., 1999, 19(2A), 1171\_1180. 11. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors H. MALONNE, I. LANGER, R. KISS, G. ATASSI. Clin. Exp. Metastasis, 1999, 11(1), 1\_18. 12. Les Céphalées chroniques journalières H. MALONNE. Neurone, 1999, 4(5), 150\_3. 13. Homocamptothecin, an E-ring modified camptothecin exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under organotypical cultures conditions P. PHILLIPART, L. HARPER, C. CHABOTEAUX, C. DECAESTECKER, Y. BRONCKART, L. GORDOVER, L. LESUEUR\_GINOT, H. MALONNE, O. LAVERGNE, D. C.H. BIGG, P. MENDES DA COSTA, R. KJSS. Clin. Cancer Res., 2000, 6(4), 1557\_62. 14. In vitro/in vivo characterisation of a tramadol HCl depot system composed of monoolein and water H. MALONNE, J. FONTAINE, A.J. MOËS. Biol. Pharm. Bull., 2000, 23(5), 627\_31. 15. Characterization of TNP\_470 induced modifications on cell proliferation and apoptosis in HUVEC and cancer cells S. FARINELLE, H. MALONNE, C. CHABOTEAUX, R. DEDECKER, T. GRAS, D. ZUNE, F. DARRO, J. FONTAINE, G. ATASSI, R. KISS., J. FONTAINE. Pharmacol. Toxicol. Methods, 2000, 43(1), 15\_24. 16. In vitro and in vivo pharmacological characterizations of the anti-tumor properties of two new olivacine derivatives, S16020\_2 and S30972\_1 H. MALONNE, S. FARINELLE, C. DECAESTECKER, L. GORDOWER, J. FONTAINE, F. CHAMINADE, J.M. SAUCIER, G. ATASSI, R. KISS. Clin. Cancer Res., 2000, 6(9), 3774\_82. 17. Développement préclinique de nouvelles molécules à visée antitumorale: études pharmacologiques et toxicologiques H. MALONNE, J. GUSMAN, G. ATASSI. J. Pharm. Belg., 2000, 55(5), 122\_30. 18. A reappraisal of potential chemopreventive and chemotherapeutic properties of resveratrol J. GUSMAN, H. MALONNE, G. ATASSI. Carcinogenesis, 2001, 22(8), 1111\_7. 19. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie I : Importance du problème D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN Louvain Med., 2001, 120(10), 354\_61. 20. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie II : Revues des options thérapeutiques D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN Louvain Med., 2001, 120(10), 362\_72. 21. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie III Revues des options thérapeutiques D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN Louvain Med., 2001, 120(10), 362\_72. 22. Cardiotoxicité du 5-fluorouracil: A propos de 6 nouveaux cas Q. TIMOUR, C. LOMBARDO\_BOHAS, R. SLIM, C. BAREL, B. BUI\_XUAN, A.TAHIB, G. BRICCA, H. MALONNE, T. VIAL, D. IORDESCU, J. DESCOTES. Thérapie, 2002, 57(3), 302\_6. 23. Differences in efficacy found in animal between recombinant forms of erythropoietin will not necessarily translate into differences in humans H. MALONNE. Br. J. Cancer, 2002, 87(4), 475\_7. 24. Conseils en pharmacie pour l'automédication de la diarrhée aiguë L. LEEMANS, J. BURTON, C. ELSEN, S. HUIJGHEBAERT, T. LESCRIER, H. MALONNE, F. NAGELS, F. NIESTEN Ann. Pharm. Belg., 2002, 52(6), 26\_42. 25. Impact of montelukast on symptoms in mild to moderate persistent asthma and exercise induced asthma: Results of the ASTHMA Survey H. MALONNE, A. LACHMAN, P. VAN DEN BRANDE Curr. Med. Res. Opin. 2002, 18(8), 512\_9. 26. Treatment of acute diarrhea: update of guidelines based on a critical interuniversity assessment of medications and current practices D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, A. VAN GOMPEL, A. VAN GOSSUM, E. VAN WIJNGAERDEN Acta Gastroenterol. Belg., 2003, 66(3), 218\_26. 27. The experience of menstrual pain in Belgian women H. MALONNE, J. VAN HOEK. In: Proceedings of the 10th World Congress on Pain, Progress in Pain Research and Management, Vol. 24, Edited by J.O. Dostrovsky, D.B. Can and M. Koltzenburg, IASP Press, Seattle, 2003, 571\_6. 28. Accidents cardio-vasculaires et coxibs; mythe ou réalité? H. MALONNE, D. FONTAINE Science et Officine, 2003, 2, 7\_11. 29. Assessment of the pharmacokinetic profile of a new once daily oral formulation of tramadol hydrochloride after single and multiple dose administration in healthy volunteers H. MALONNE, B. SONET, B. STREEL, S. LEBRUN, S. DE NIET, A. SERENO, F. VANDERBIST Br. J. Clin. Pharmacol. 2004, 57(3), 270\_8. 30. Phenolic compounds from Plumbago zeylanica and their cytotoxicity A.T. NGUYEN, H. MALONNE, P. DUEZ, R. VANHAELLEN\_FASTRE, M. VANHAELLEN, J. FONTAINE Fitoterapia, 2004, 75(5), 500\_4. 31. Aspects physiologiques et pharmacologiques des érythropoïétines H. MALONNE J. Pharm. Belg., 2004, 59(2), 41\_8. 32. Efficacy of sustained release tramadol in the treatment of symptomatic osteoarthritis of the knee and of the hip: A randomised, multicentre, placebo controlled, double blind study H. MALONNE, M. COFFINER, B. SONET, A. SERENO, F. VANDERBIST Clin. Ther., 2004, 26(11), 1774\_82. 33. Long term tolerability of a new once daily tramadol formulation in patients with osteoarthritis or low back pain H. MALONNE, M. COFFINER, D. FONTAINE, B. SONET, A. SERENO, A. PERETZ, F. VANDERBIST J. Clin. Pharm. Ther., 2005, 30(2), 113\_20. 34. A sugar ester and an iridoid glycoside from Scrophularia ningpoensis. A.T. NGUYEN, J. FONTAINE, H. MALONNE, M. CLAEYS, M. LUHMER, P. DUEZ Phytochemistry, 2005 May, 66(10), 1186\_91. 35. Preliminary assessment of the acute and subacute toxicity of poly(Nisopropylacrylamide) and copolymers in mice H. MALONNE, F. EECKMAN, D. FONTAINE, A. OTTO, L. DE VOS, A. MOËS, J. FONTAINE, K. AMIGHI Eur. J. Pharm. Biopharm., 2005 Oct, 61(3), 188\_94. 36. Cytotoxicity of five plants used as anticancer remedies in Vietnamese traditional medicine A.T. NGUYEN, J. FONTAINE, H. MALONNE, M. VANHAELLEN, J. DUBOIS, T.K. PHAM, P. DUEZ In: Recent Progress in Medicinal Plants, Edited by V.K. SINGH, ARUNACHALAM V.K. SINGH, J.N. GOVIL, Studium Press LLC, New Delhi, 2006, 145\_155. 37. Homoisoflavanones from Disporopsis aspera. A.T. NGUYEN, J. FONTAINE, H. MALONNE, P. DUEZ Phytochemistry, 2006 Oct, 67(19), 2159\_63. 38. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy induced nausea and vomiting in Belgium. L. ANNEMANS, D. STRENS, E. LOX, C. PETIT, H. MALONNE Support Care Cancer, 2008 Aug, 16(8), 905\_15. 39. The role of serology for COVID-19 control: Population, kinetics and test performance do matter. M. TRE\_HARDY, L. BLAIRON L, A. WILMET, I. BEUKINGA, H. MALONNE, JM DOGNE, J. DOUXFILS J Infect. 2020 Aug;81(2):e91\_e92. 40. Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load. P. MESTDAGH, M. GILLARD, SK DHILLON, JP PIRNAY, J. POELS, J. HELLEMANS, V. HUTSE, C. VERMEIREN, M. BOUTIER, V. DE WEVER, P. SOENTJENS, S. DJEBARA, H. MALONNE, E. ANDRÉ, M. ARBYN, J. SMERAGLIA, J. VANDESOMPELE. J Mol Diagn. 2021 Oct;23(10):1249\_1258.

## Projects

## Memberships

Presentations at congresses 1. Potential depot systems composed of polar lipids and water H. MALONNE, A.J. MOËS, J. FONTAINE. Proceedings of the 2nd European Intensive Course on New Forms and New Routes of Administration for Drugs, Parme, Italie, 1996. 2. Antitumour activity of S 16020\_2 (NSC\_659687) in the MXT mouse mammary carcinoma model H. MALONNE, S. FARINELLE, J. FONTAINE, R. KISS, G. ATASSI. Proceedings of the 6th International Conference of Anticancer Research, Halkidiki, Grèce, 1998 (publié dans Anticancer Res., 1998, 18, 4910). 3. In vitro characterization of S 16020\_2 induced effects on Human Umbilical Vein Endothelial Cells lines H. MALONNE, S. FARINELLE, J. FONTAINE, G. ATASSI, R. KISS. Proceedings of the 6th International Conference of Anticancer Research, Halkidiki, Grèce, 1998 (publié dans Anticancer Res., 1998, 18, 4910). 4. Histological characterisation of a highly invasive and metastatic model originating from the P388 leukemia cell line H. MALONNE, S. FARINELLE, D. FONTAINE, J. FONTAINE, R. KISS, G. ATASSI. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, RUG, Gand, Belgique, 1999 (publié dans Pflugers Arch., 1999, 437, R30). 5. Pharmacological characterization of two new olivacine derivatives as potential anticancer drugs H. MALONNE, S. FARINELLE, C. DECAESTECKER, J. FONTAINE, R. KISS, G. ATASSI. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Campus Erasme, ULB, Bruxelles, Belgique, 2000 (publié dans Pflugers Arch., 2000, 440, R7). 6. Characterisation of a tramadol HCl depot system composed of monoolein and water H. MALONNE, J. FONTAINE, A.J. MOËS. (Présentation orale) 9ème Forum de la Société Belge des Sciences Pharmaceutiques, Blankenberge, Belgique, 2000 (publié dans J. Phann. Belg., 2000). 7. Quantitative assessment of angiogenesis in the chick embryo chorioallantoic membrane assay and the effect of chitosan. M.MALEKI, L.DEWACHTER, K.AMIGHI, H.MALONNE, J.FONTAINE 68ème Congrès de la Société de Physiologie, Liège, Belgique, 2000 (publié dans Pflugers Arch., 2000, 440, R233\_4). 8. Characterization of the effect of chitosan on angiogenesis in the chick embryo chorioallantoic membrane assay. H.MALONNE, M.MALEKI, L..DEWACHTER, K.AMIGHI,

J.FONTAINE VIIIth International Metastasis Research Society Congress, Londres, Royaume-Uni, 2000 (publié dans Clin. Exp. Metastasis, 1999, 11, 777). 9. Evaluation of different formulations of Paclitaxel nanoparticles K. AMIGHI, I. GIL\_DELGADO, H.MALONNE, J. GUSMAN, J.FONTAINE 10ème Forum de la Société Belge des Sciences Pharmaceutiques, Montréal Canada, 2001. 10. Evaluation of the pharmacokinetic profile of a new once daily oral formulation of tramadol hydrochloride in healthy volunteers F.VANDERBIST, B. SONET, S. LEBRUN, S. DENIET, A. SERENO, H. MALONNE. 3ème Réunion de la Fédération des 25 Sociétés Européennes de Pharmacologie (EPHAR), Lyon, France, 2001 (publié dans Fund. Clin. Pharmacol., 2001.15.Sup 1, 30). 11. Preparation and characterization of paclitaxelloaded nanoparticles I. GIL\_DELGADO, H. MALONNE, J. GUSMAN, J.FONTAINE, K. AMIGHI. International Symposium on Materials Characterisation and Technology Bruxelles, Belgique 2001. 12. Comparative pharmacodynamics and pharmacokinetics of triptans H. MALONNE. (Oral presentation) Neurogenetics and acute treatment of migraine. Autumn meeting of the BNS (Belgian Neurological Society). Spa, Belgique. 2001. 13. Mechanism of 5-fluorouracil cardiotoxicity: spasm, apoptosis or necrosis? Q. TIMOUR, C. LOMBARD-BOHAS, D. IORDACHESCU, B. BUI\_XUAN, H. MALONNE, T. VIAL, J. DESCOTES, L. CHALABREYSSE, A. TABIB. IUPHAR, San Francisco (Ca), Etats-Unis, 2002. 14. Belgian women and menstrual pain H. MALONNE, O. BAYARD, M. FOULON, M. VANSCHOOR, A. VIOLON, J. WIELANDT, L. GOUBERT, J. VAN HOEK. 10th World Congress on Pain, International Association for the Study of Pain, San Diego (Ca), Etats-Unis, 2002. 15. Les Cercles de Qualité; Interactions Pharmaciens\_Médecins, le meilleur des deux mondes? H.MALONNE. Colloque «regards croisés sur la Pharmacie d'officine» Ecole de Pharmacie, Université catholique de Louvain, Bruxelles, 2002. 16. Evaluation of the antiangiogenic potential of ACE inhibitors on the chick chorioallantoic membrane model C. CZERWONOGORA, D. FONTAINE, H. MALONNE, J. FONTAINE Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, RUG, Gand, Belgique, 2002 (publié dans Fund. Clin. Pharmacol., 2003, 11(3), 272). 17. Isolation and structure determination of potential cytotoxic constituents from *Plumbago zeylanica* A.T. NGUYEN, H. MALONNE, P. DUEZ, R. VANHAELLEN\_FASTRE, J. FONTAINE, M. VANHAELLEN 27th Landelijk Overleg Farmacognosie Symposium (LOF), Anvers, Belgique, 2003. 18. The ASTHMA Survey: impact of montelukast on symptoms in mild to moderate persistent asthma and exercise-induced asthma H. MALONNE, A. LACHMAN, P. VAN DEN BRANDE 60th Anniversary Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI), Denver (Co), Etats-Unis, 2003 (publié dans J. Allergy Clin. Immunol., 2003, 111(2), S144). 19. A phytochemical analysis and cytotoxic study of 2 Vietnamese medicinal plants *Scrophularia ningpoensis* Hemsl. and *Disporopsis aspera* Engl. A.T. NGUYEN, H. MALONNE, J. FONTAINE, M. VANHAELLEN, P. DUEZ. 51st Annual Congress of the Society for Medicinal Plant Research, Kiel, Allemagne, 2003. 20. Open, international, multicentre, PHASE III trial on the safety of a long-term treatment with a new sustained-release formulation of tramadol in patients suffering from osteoarthritis or from refractory chronic low back pain H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, A. PERETZ, F. VANDERBIST Pain in Europe IV, 4th Congress of the European Federation of IASP Chapters (EFIC), Prague, Tchéquie, 2003. 21. Randomised multicentre double-blind placebo-controlled study comparing the efficacy of slow release tramadol with immediate release tramadol in the treatment of symptomatic osteoarthritis of the knee and of the hip H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, F. VANDERBIST World Congress on Osteoarthritis, Osteoarthritis Research Society International (OARSI), Berlin, Allemagne, 2003 (publié dans Osteoarthritis Cartilage, 2003, 11(Suppl. A.), S118). 22. L'étoricoxib, un AINS de nouvelle génération? H. MALONNE Symposium satellite MSD, Congrès européen "Le Clinicien face à la Douleur Chronique" sous l'égide du Collège International Francophone de Pathologie Ostéoarticulaire, Bruxelles, Belgique, 2004. 23. Phenolic compounds from *Plumbago zeylanica* and their cytotoxicity A.T. NGUYEN, J. FONTAINE, H.MALONNE, M. VANHAELLEN, P. DUEZ. 12ème Forum de la Société Belge des Sciences Pharmaceutiques, Blankenberghe, Belgique, 2004. 24. Randomised multicentre double-blind study comparing the efficacy of slow release tramadol versus placebo in the treatment of symptomatic osteoarthritis of the knee or the hip H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, A. SERENO, F. VANDERBIST Annual European Congress of Rheumatology, European League Against Rheumatism (EULAR), Berlin, Allemagne, 2004 (publié dans Ann. Rheum. Dis., 2004, 63(Suppl.1), 370). 25. Phenylpropanoid and iridoid glycosides from *Scrophularia ningpoensis* A.T. NGUYEN, J. FONTAINE, M. CLAEYS, F. NSUADI, H. MALONNE, P. DUEZ. International Congress on Natural Products Research, Phoenix, Arizona, USA, 2004. 26. Experience with ibuprofen lysine in patient with acute mild to moderate pain: Results of the "Paincare" survey H. MALONNE, D. FONTAINE 3rd WIP Congress, International Institute of Pain, Barcelona, Spain, 2004 (publié dans Pain Pract., 2004, Book of Abstract, 281\_2). 27. Synthèse des études cliniques sur la substitution hormonale H. MALONNE Symposium sur la prise en charge de la ménopause, Centre Universitaire de Médecine Générale de l'Université Libre de Bruxelles, Diegem, Belgique, 2004. 28. Cost evaluation of erythropoiesis stimulating agents in the treatment of platinum chemotherapy-induced anaemia H. MALONNE 20th General Meeting of the Belgian Hematological Society (BHS), Genval, Belgique 2005 29. The Switch from epoetins to darbepoetin in dialysis patients: A cost evaluation H. MALONNE Réunion annuelle de la Société Belge de Néphrologie, Bruxelles, Belgique, 2005. 30. New and cytotoxic compounds from *Disporopsis aspera* A.T. NGUYEN, J. FONTAINE, H. MALONNE, P. DUEZ. 53rd Annual Meeting of the Society for Medicinal Plant Research, Florence, Italie, 2005. 31. Structure elucidation and biological evaluation of cytotoxic constituents from *Scrophularia ningpoensis* and *Disporopsis aspera* A.T. NGUYEN, J. FONTAINE, H. MALONNE, P. DUEZ. Journées de l'école doctorale en Sciences Pharmaceutiques, Bruxelles, Belgique, 2005. 32. Cost evaluation of the switch from epoetins to darbepoetin in dialysis patients H. MALONNE ERA EDTA XLII Congress, Istanbul, Turkey, 2005. 33. Utilization and costs of epoetins and darbepoetin for treating chemotherapy-induced anaemia H. MALONNE ECCO\_ESTRO, 13th European Conference on Clinical Oncology & 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, Paris, France, 2005. 34. Utilization and costs of epoetins and darbepoetin for treating platinum chemotherapy-induced anaemia H. MALONNE American Society of Clinical Oncology, Annual Meeting, San Francisco, 2005. 35. PITS is an effective strategy for providing testing services to large numbers of people in a short time in resource-limited settings in South-West China H. MALONNE AIDS 2010 XVIII International AIDS Conference, Vienna, Austria, 2010. 36. Study on effect of provider initiated HIV testing and consulting (PITS) at areas inhabited by ethnic minorities with high HIV epidemic L. CHONGXING, G. YUHAN, L. PENG, L. HUI, L. ZHONGFU, H. YUCHUAN, H. MALONNE 6th IAS Conference on HIV Pathogenesis Treatment and Prevention, Rome, Italy, 2011. 37. Best Practices on HIV/AIDS Comprehensive Prevention and Control in Liang Shan Prefecture, Sichuan Province, People's Republic of China L. CHONGXING, G. YUHAN, L. PENG, L. HUI, L. ZHONGFU, H. YUCHUAN, H. MALONNE The 10th International Congress on AIDS in Asia and the Pacific (ICAAP10), Pusan, South Korea, 2011.

## Other Relevant Information